| Home > Publications database > Should there be informed decision-making for prostate cancer screening? An analysis of preference sensitivity. |
| Journal Article | DKFZ-2026-02004 |
;
2026
Sage
London [u.a.]
Abstract: BackgroundAlmost all national guidelines groups recommend that individual men make an informed personal decision about whether to be screened for prostate cancer. This implies the decision to undergo prostate-specific antigen (PSA) testing is preference sensitive; that is, whether the expected utility of screening is higher or lower than that of no screening can vary depending on a man's preferences ('utilities') for downstream health states such as urinary incontinence.MethodsWe reviewed the literature to find evidence on whether PSA screening is indeed a preference-sensitive decision.ResultsWe found that preference sensitivity was routinely asserted without providing any evidence. Some authors pointed to studies of PSA decision aids, but there is no logical link between a decision aid changing a decision and that decision being preference sensitive. The major modeling study on PSA screening found higher expected utility for PSA screening irrespective of how a man might feel about the side-effects of treatment. One study did find that while PSA screening was generally favored, expected utility was fractionally lower in a small subgroup, but the difference was extremely small, and would not be negative with recent changes to PSA screening pathways.ConclusionThe assumption underlying informed choice policies-PSA screening is a preference-sensitive decision-is not supported by the literature. Men should be provided with clear information about and give consent for PSA testing, but preference elicitation as part of shared decision-making is not indicated.
Keyword(s): PSA screening ; Prostate cancer ; decision analysis ; preference sensitivity ; shared decision making
|
The record appears in these collections: |